Kisqali
(Dalpiciclib)Phase 3Small molecule
Dalpiciclib is used to treat certain types of breast cancer, specifically hormone receptor-positive breast cancer in women. It works by slowing down the growth of cancer cells.[1] Kisqali is currently being investigated across 5 indications[3], with its most advanced program in Phase 3.[1]
Kisqali is one of 188 small molecule programs targeting Esophageal Squamous Cell Carcinoma. It is currently in Phase 3.
5
Indications
34
Total Trials
27
Active Trials
187
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
702 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Kisqali
RRisen (Suzhou) Pharma Tech Co., Ltd.
Phase 3
Adenocard
AstellasPreclinical
Lexiscan
AstellasPreclinical
Zolymbus
AbbViePreclinical
Blenoxane
Bristol-Myers SquibbPreclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
Spravato
WWim Janssens
Preclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Duragesic
CCephalon
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Breast Cancer24 trials
Show 21 more trials
Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase Ⅰb Study
Unknown status·—·Phase 1·NCT05586841·30 enrolled
Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer
Active, not recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT05463601·132 enrolled
Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor
Not yet recruiting·—·Phase 2·NCT06556862·155 enrolled
Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer
Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06341894·1,163 enrolled
Dalpiciclib2 trials
Ovarian Cancer1 trial
Adjuvant Therapy1 trial
5 more indications
Head and Neck Squamous Cell Carcinoma1 trial
Metastatic Colorectal Cancer1 trial
Metastatic Breast Cancer (MBC)1 trial
An Open-Label, Multicenter Clinical Study of Trastuzumab Rezetecan Followed by Pyrotinib in Combination With Fulvestrant and Dalpiciclib in Patients With HR-Positive, HER2-Positive Advanced Breast Cancer
Not yet recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 3·NCT07892274·226 enrolled
Meningioma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Dalpiciclib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details